Published in Cancer Weekly, May 5th, 2009
IST has genetically engineered an antibody drug that binds specifically to a target protein found on the surface of some blood cancer cells. Laboratory studies, using cells taken from patients with a type of blood cancer called multiple myeloma, have shown that the antibody works with the human immune system to induce death of the cancer cells. It is anticipated that the antibody will potentially reduce the number of cancerous cells in multiple myeloma patients and improve patient health and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly